Inovio Pharmaceuticals. has filed a patent for a method of treating or preventing vulvar dysplasia using anti-HPV immunogens and nucleic acid molecules. The method involves administering a composition containing nucleic acid molecules that encode HPV16 or HPV18 antigens to induce an immune response. This patent aims to provide a new approach for the treatment and prevention of vulvar dysplasia. GlobalData’s report on Inovio Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Inovio Pharmaceuticals, Personalized cancer vaccines was a key innovation area identified from patents. Inovio Pharmaceuticals's grant share as of September 2023 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for a method to treat or prevent vulvar dysplasia using nucleic acid molecules encoding hpv antigens
A recently filed patent (Publication Number: US20230277645A1) describes a method for treating or preventing vulvar dysplasia in an individual. The method involves administering a composition containing at least one nucleic acid molecule encoding either an HPV16 antigen or an HPV18 antigen.
The patent claims specify various aspects of the method. Claim 2 states that the HPV16 antigen used is an HPV16 E6-E7 fusion antigen, while claim 3 specifies that the HPV18 antigen used is an HPV18 E6-E7 fusion antigen. Claim 4 mentions that the composition includes a nucleotide sequence encoding both the HPV16 and HPV18 antigens.
Claims 5 to 8 provide further details about the nucleic acid molecule used in the composition. These claims describe different nucleotide sequences that can be present, including sequences that encode a specific antigen (SEQ ID NO:2) or are homologous to it. Claims 9 to 11 describe similar details for the nucleic acid molecule encoding the HPV16 antigen, while claims 12 to 14 do the same for the nucleic acid molecule encoding the HPV18 antigen.
The patent also covers the use of a leader sequence in the nucleotide sequences encoding the HPV16 E6-E7 fusion antigen (claim 15) and provides additional options for the nucleic acid molecule encoding the HPV18 antigen (claims 16 to 18).
Other aspects of the method mentioned in the patent include the use of plasmids as nucleic acid molecules (claim 19), the composition being a pharmaceutical composition (claim 20), and the administration of an adjuvant along with the composition (claim 21).
Lastly, claim 22 describes a specific combination of nucleotide sequences encoding the HPV16 and HPV18 antigens. The nucleotide sequence encoding the HPV16 E6-E7 fusion antigen can be SEQ ID NO:2 or a homologous sequence, while the nucleotide sequence encoding the HPV18 E6-E7 fusion antigen can be SEQ ID NO:10 or a homologous sequence.
The method of administering the nucleic acid molecule to the individual can involve electroporation, as mentioned in claim 23.
In summary, the patent describes a method for treating or preventing vulvar dysplasia by administering a composition containing nucleic acid molecules encoding HPV16 and/or HPV18 antigens. The patent covers various specific nucleotide sequences, the use of plasmids, pharmaceutical compositions, adjuvants, and the option of electroporation for administration.
To know more about GlobalData’s detailed insights on Inovio Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
